Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
The much criticised takeover of Idera by Biocryst will not, after all, take place.